ADVERTISEMENT

Dassault to Buy Medidata in $5.7 Billion Health Data Push

The all-cash transaction values Medidata at $92.25 a share -- 17% more than Medidata’s closing price on April 18.

Dassault to Buy Medidata in $5.7 Billion Health Data Push
A research technologist prepares a Tessa Therapeutics Pte. virus specific t-cells (VST) infusion for cancer patients as part of a clinical trial inside a good manufacturing practice (GMP) room at Singapore’s National Cancer Center (NCCS) in Singapore. (Photographer: Nicky Loh/Bloomberg)

(Bloomberg) -- Dassault Systemes SE, a maker of industrial design software, agreed to buy Medidata Solutions Inc. for $5.7 billion to gain a foothold in the fast-growing market for clinical trial technology.

The deal pushes the French company further beyond its design roots into data processing and business analysis. Medidata’s software analyzes pharmaceutical and biotech trials for some of the world’s biggest drugmakers including Sanofi SA, Pfizer Inc. and AstraZeneca Plc.

“This is by far the largest acquisition we’ve ever made,” Pascal Daloz, chief financial officer of Dassault Systemes, said on a conference call. He said health is becoming a crucial market for the company, whose customers are mostly in aerospace, defense and consumer goods.

The all-cash deal values New York-based Medidata at $92.25 a share, 17% above its closing price on April 18, the last trading day before Bloomberg reported Dassault Systemes’ interest in the company. Medidata stock fell 4.4% to $90.60 in premarket trading.

Shares in Dassault Systemes, which has a market value of 36 billion euros ($41 billion) and annual sales of 3.5 billion euros last year, fell as much as 3% before recouping some of the decline to trade down 1% at 11:31 a.m. in Paris.

Personalized Medicine

Medidata offers clients wearable sensors that help track patient health and biomarker analysis to select which patients may best respond to certain drugs. It estimates that 13 of the top 15 medicines sold last year relied on its technology, as the healthcare industry shifts towards personalized medicine and the targeting of individual patient profiles.

President Donald Trump’s protectionist trade agenda hasn’t reduced the appetite of European companies for U.S. takeovers. In fact their appeal has been growing, potentially turning the tables after years in which Europe was mostly a target for U.S. acquirers.

French advertising group Publicis Groupe SA announced its biggest ever takeover in April, a $4.4 billion deal for U.S.-based Alliance Data Systems Corp.’s digital marketing unit Epsilon.

The Medidata deal is expected to close in the final quarter of 2019 and start boosting earnings as early as 2020, the companies said in a statement. Dassault Systemes will finance it with a 1 billion-euro loan, a 3 billion-euro bridge-to-loan facility and available cash. It’s the first time the French company has resorted to external funding, Daloz said.

--With assistance from Liana Baker, Manuel Baigorri, Ruth David, Ed Hammond and Marthe Fourcade.

To contact the reporters on this story: Marie Mawad in Paris at mmawad1@bloomberg.net;Geraldine Amiel in Paris at gamiel@bloomberg.net

To contact the editors responsible for this story: Giles Turner at gturner35@bloomberg.net, Thomas Pfeiffer, Frank Connelly

©2019 Bloomberg L.P.